
Autolus Therapeutics (AUTL) Stock Forecast & Price Target
Autolus Therapeutics (AUTL) Analyst Ratings
Bulls say
Autolus Therapeutics PLC is positioned for growth due to its robust clinical-stage pipeline, which features multiple promising T-cell therapies, including Obe-cel, that may demonstrate enhanced efficacy compared to standard-of-care CAR-T options. The company expects to achieve substantial improvements in manufacturing efficiencies, potentially driving gross margins upward to 60-70% over time. The demonstrated safety and mortality benefits of its lead therapy, Aucazyl, in real-world applications further solidify its competitive advantage and potential for increased market adoption in treating refractory acute lymphoblastic leukemia.
Bears say
Autolus Therapeutics faces significant challenges, as projected sales are anticipated to remain flat in the third quarter of 2025 due to recent changes in CMS reimbursement policies. The company's development of CAR-T therapeutics appears to be insufficient, with early clinical results indicating potential shortfalls in production capability and effectiveness. Additionally, the emergence of patient relapses and minimal reductions in disease scores raise concerns about the reliability of their therapies, further contributing to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Autolus Therapeutics (AUTL) Analyst Forecast & Price Prediction
Start investing in Autolus Therapeutics (AUTL)
Order type
Buy in
Order amount
Est. shares
0 shares